Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBIO-600 in Overweight or Obese Adult Participants
NCT07487376Phase 1Recruiting
- Sponsor
- iBio
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBIO-600 in obesity (5 arms), sponsored by iBio. Primary endpoint: Assessment of the safety and tolerability of a single dose. Started May 2026; status: recruiting.
02
Drugs
IBIO-600
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07487376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07487376.